高级搜索

贲门癌中巨噬细胞移动抑制因子表达与患者临床病理特征及预后的关系

徐海涛, 张连国, 刘建伟, 刘洪建, 张庆广

徐海涛, 张连国, 刘建伟, 刘洪建, 张庆广. 贲门癌中巨噬细胞移动抑制因子表达与患者临床病理特征及预后的关系[J]. 肿瘤防治研究, 2016, 43(9): 779-782. DOI: 10.3971/j.issn.1000-8578.2016.09.010
引用本文: 徐海涛, 张连国, 刘建伟, 刘洪建, 张庆广. 贲门癌中巨噬细胞移动抑制因子表达与患者临床病理特征及预后的关系[J]. 肿瘤防治研究, 2016, 43(9): 779-782. DOI: 10.3971/j.issn.1000-8578.2016.09.010
XU Haitao, ZHANG Lianguo, LIU Jianwei, LIU Hongjian, ZHANG Qingguang. Relationship of Macrophage Migration Inhibitory Factor Expression with Clinicopathologic Features and Prognosis of Cardiac Carcinoma Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 779-782. DOI: 10.3971/j.issn.1000-8578.2016.09.010
Citation: XU Haitao, ZHANG Lianguo, LIU Jianwei, LIU Hongjian, ZHANG Qingguang. Relationship of Macrophage Migration Inhibitory Factor Expression with Clinicopathologic Features and Prognosis of Cardiac Carcinoma Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 779-782. DOI: 10.3971/j.issn.1000-8578.2016.09.010

贲门癌中巨噬细胞移动抑制因子表达与患者临床病理特征及预后的关系

详细信息
    作者简介:

    徐海涛(1982-),男,硕士,主治医师,主要从事胸部恶性肿瘤的外科治疗及基础研究

    通讯作者:

    张庆广.E-mail: drzhangqingg@126.com

  • 中图分类号: R735

Relationship of Macrophage Migration Inhibitory Factor Expression with Clinicopathologic Features and Prognosis of Cardiac Carcinoma Patients

More Information
  • 摘要:
    目的 

    探讨巨噬细胞移动抑制因子(macrophage migration inhibitory factor, MIF)在贲门癌中的表达及其与患者临床病理特征和预后的关系。

    方法 

    选取滨州医学院附属医院胸外科2008年1月—2009年12月经胸手术切除的贲门癌石蜡标本73例,采用免疫组织化学法检测贲门癌组织中MIF的表达水平,根据免疫反应强弱将其分为高表达组和低表达组,分析MIF表达水平与患者临床病理特征的关系,Kaplan-Meier生存曲线比较MIF高表达组和低表达组患者的生存期,Cox回归模型分析MIF的表达水平与临床病理特征及患者预后的关系。

    结果 

    MIF在贲门癌组织中高表达42例,高表达率为57.5%。MIF表达水平与患者的年龄、性别、肿瘤分化程度、淋巴结转移和TNM分期无关(P>0.05),与肿瘤的浸润深度有关(P=0.025)。MIF高表达组和低表达组的生存期用Kaplan-Meier方法评估,并用Log rank检验进行比较,两组之间生存率差异有统计学意义(P=0.001)。多因素Cox回归模型分析表明,淋巴结转移(P=0.025)、MIF表达水平(P=0.001)是影响贲门癌预后的独立危险因素。

    结论 

    MIF的表达异常可能在贲门癌的浸润及预后中有重要作用,对患者预后的判断有一定指导意义。

     

    Abstract:
    Objective 

    To investigate the expression of macrophage migration inhibitory factor (MIF) in cardiac carcinoma and its correlation with clinicopathologic features and prognosis.

    Methods 

    The paraffin specimens from 73 patients with cardiac carcinoma who underwent thoracotomy were collected from the Affiliated Hospital of Binzhou Medical University from 2008-01-03 to 2009-12-31. The expressions of MIF in 73 specimens of cardiac carcinoma were assessed by immunohistochemistry. Based on the levels of MIF immunoreactivities, the 73 specimens were divided into high MIF expression group and low MIF expression group, and the correlations of MIF expression with clinicopathologic features was analyzed. Kaplan-Meier survival curves were used to compare the survival between high MIF expression group and low MIF expression group. The correlations of MIF expression with clinicopathologic features and the prognosis of cardiac carcinoma patients were analyzed by Cox regression model.

    Results 

    The high MIF expression rate was 57.5%. There was no significant correlation between the levels of MIF expression and age, gender, tumor differentiation, lymph node metastasis, TNM stages(P>0.05). However, the high MIF expression was strongly correlated with the depth of invasion(P=0.025). The survival rates were significantly different between the two groups(P=0.001). The multivariate Cox regression model analysis showed that lymph node metastasis(P=0.025) and the levels of MIF expression(P=0.001) were the independent prognostic risk factors for cardiac carcinoma.

    Conclusion 

    The abnormal of MIF expression in cardiac carci noma may play an important role in tumor infiltration and prognosis. MIF could be a valuable prognostic factor for the patients with cardiac carcinoma.

     

  • 巨噬细胞移动抑制因子(macrophage migration inhibitory factor,MIF)作为炎症细胞因子,存在于淋巴细胞、巨噬细胞及各种组织实质和间质细胞中,具有多种生物活性,在内毒素休克、炎性反应、移植排斥反应等中起重要作用。目前发现MIF是一种独特的促进恶性肿瘤发生发展的细胞因子,几乎参与了肿瘤发生、发展的全部阶段[1]。MIF在大多数肿瘤中表达并参与肿瘤发展的过程,使其有可能成为肿瘤治疗的新靶点[2-3]。本研究采用免疫组织化学法检测在手术切除的贲门癌标本中MIF的表达,探讨其与患者临床病理特征、预后的关系。

    选取滨州医学院附属医院胸外科2008年1月—2009年12月经胸手术切除的贲门癌石蜡标本73例,其中男64例、女9例,年龄41~81岁,中位年龄64岁。所有病例均有完整的临床病理资料,见表 1。根据第7版AJCC胃癌TNM分期标准。10例胃正常组织标本取自贲门癌手术标本距肿瘤边缘3 cm以上的胃切缘。

    鼠抗人单克隆抗体MIF购自英国Abcam公司(上海艾博抗公司代购),浓缩型DAB试剂盒、通用型二步法PV-9000免疫组织化学试剂盒购自北京中杉金桥生物技术有限公司。

    采用免疫组织化学Elivison二步法。将术后常规石蜡包埋的组织制成4 μm切片,脱蜡至水。置于枸橼酸盐修复液中(10 mmol/L,pH6.0),微波炉加热(100℃,10 min)行抗原修复,蒸馏水冲洗2次,磷酸盐缓冲液(PBS)洗3次,每次5 min;3%H2O2室温孵育10 min去除内源性过氧化物酶,PBS洗3次;按1:120稀释鼠抗人单克隆抗体MIF,加一抗后4℃过夜;PBS洗3次,加1滴聚合物增强剂(试剂A),室温孵育20 min后,PBS洗3次,滴加酶标抗鼠/兔聚合物(试剂B),室温孵育30 min,PBS洗3次;DAB显色,脱水透明,中性树胶封片。

    两位病理科医生应用双盲法观察确定。每例均随机观察5个高倍镜视野。用半定量积分法判断结果,(1)染色强度:0分为无色,1分为淡黄色,2分为棕黄色,3分为棕褐色。(2)阳性细胞所占百分比:0分为阴性,1分为阳性细胞≤10%,2分为阳性细胞10%~50%,3分为阳性细胞50%~75%,4分为阳性细胞>75%。两项记分相乘为最后结果,分为阴性(0~1分),弱阳性(2~4分),阳性(6~8分),强阳性(9~12分),其中阴性和弱阳性为低表达,阳性和强阳性为高表达。

    所有患者均获随访。随访时间从确定贲门癌手术之日起开始计算,即随访开始时间为2008年1月3日,随访时间截至2015年1月5日。随访方式为患者复诊、电话及其他方式。生存时间为自手术日至患者死亡时间或随访截止时间。

    采用SPSS19.0统计软件进行数据处理,MIF表达与临床病理特征之间的关系采用Pearson χ2检验。Kaplan-Meier法绘制生存曲线,Log rank检验比较两组生存曲线有无差异。Cox回归模型行多因素分析。P<0.05为差异有统计学意义。

    免疫组织化学结果显示,在73例贲门癌患者中,MIF高表达42例,高表达率为57.5%,低表达31例,低表达率为42.5%。MIF的阳性表达主要定位于肿瘤细胞的细胞质,癌旁正常胃组织不表达,见图 1~2

    图  1  贲门癌组织中MIF的表达 (IHC×400)
    Figure  1  Expression of MIF in cardiac carcinoma tissues (IHC×400)
    A: low MIF expression; B: high MIF expression
    图  2  胃正常组织中MIF的阴性表达 (IHC×400)
    Figure  2  Negative MIF expression in gastric mucosae tissues (IHC×400)

    MIF表达水平与患者的年龄、性别、肿瘤分化程度、有无淋巴结转移和TNM分期无关(P>0.05),与肿瘤的浸润深度有关(P=0.025),见表 1

    表  1  MIF表达与贲门癌患者临床病理特征的关系
    Table  1  Relationship between MIF expression and clinicopathological features of cardiac carcinoma patients
    下载: 导出CSV 
    | 显示表格

    73例贲门癌患者中,术后5年生存率为24.7%。MIF高表达患者与低表达患者术后5年生存率分别为14.3%、38.7%。MIF高表达组和低表达组的生存期用Kaplan-Meier方法评估,并用Log rank检验进行比较,两组之间生存率差异有统计学意义(P=0.001),见图 3。多因素Cox回归模型分析表明,淋巴结转移、MIF表达水平是影响贲门癌患者预后的独立危险因素(P<0.05),见表 2

    图  3  MIF高表达和低表达与贲门癌患者5年生存率的关系
    Figure  3  Relationship between high and low expression of MIF and 5-year survival rates of cardiac carcinoma patients
    表  2  贲门癌患者多因素Cox模型分析结果
    Table  2  Multivariate analysis of cardiac carcinoma patients by Cox regression
    下载: 导出CSV 
    | 显示表格

    MIF是一种多功能细胞因子,在炎性反应、免疫抑制及肿瘤的发展中发挥着重要的作用。它使巨噬细胞获得吞噬、黏附和迁移等功能,并通过多种信号转导通路,直接或间接影响着肿瘤的生长、增殖、浸润和转移[4]。目前,越来越多的研究表明,MIF在肺癌[5]、食管癌[6]、胃癌[7]、鼻咽癌[8]、骨肉瘤[9]等多种恶性肿瘤中均有表达,并与肿瘤预后有关。

    在肿瘤形成过程中,炎性细胞产生有利于肿瘤生长的微环境,促进肿瘤细胞增殖[10]。贲门所在部位特殊,黏膜受胃酸长期刺激,易引起慢性炎症,有研究表明胃食管返流是贲门癌发生的独立危险因素[11]。本研究结果表明MIF在贲门癌组织中高表达与肿瘤浸润深度有关,说明MIF作为人体内重要的致炎因子参与了贲门癌的发生,提示MIF在贲门癌的生长、浸润过程中起着重要的作用。有研究表明[12],胃癌组织中幽门螺旋杆菌L型感染与MIF表现呈正相关,且MIF与肿瘤浸润深度有关,说明MIF既参与了炎性反应,又参与了肿瘤的生长。体外实验证实,C57BL6小鼠肺组织损伤修复过程中,MIF异常表达导致肿瘤生长,而MIF基因敲除后,未能促进肿瘤生长[13]。另外,用靶向MIF的siRNA干扰MIF后,大肠癌CT-26细胞增殖受到抑制[14]。均表明MIF通过某种途径参与肿瘤的发生、发展。

    贲门癌的发病率呈上升趋势,因其有独特的解剖学部位和生物学特性,预后较差。本组贲门癌患者术后5年生存率为24.7%,与国内的研究报道相近[15]。已有研究表明肿瘤浸润深度、淋巴结转移及病理分期等为影响贲门癌患者预后的因素[16-17]。本研究也表明淋巴结转移为影响贲门癌预后的独立危险因素。为进一步探讨MIF表达与贲门癌患者生存的关系,MIF高表达组和低表达组的生存期用Kaplan-Meier方法评估,并用Log rank检验进行比较,两组之间生存率差异有统计学意义。MIF高表达组患者术后5年生存期明显低于MIF低表达组患者,提示MIF的表达水平可以影响贲门癌的生物学行为,是预后不良的指征,可以作为评估贲门癌患者生存期的生物学指标。同时经多因素分析,淋巴结转移和MIF表达水平是影响贲门癌患者预后的独立危险因素。提示贲门癌组织中MIF的表达水平对患者预后的判断有一定的指导意义。

    综上所述,MIF高表达与贲门癌的浸润具有密切的关系,MIF表达增高提示贲门癌患者预后不良。MIF可作为一个影响贲门癌浸润和判断预后不良的指标,其参与肿瘤发展的途径应进一步研究。

  • 图  1   贲门癌组织中MIF的表达 (IHC×400)

    Figure  1   Expression of MIF in cardiac carcinoma tissues (IHC×400)

    图  2   胃正常组织中MIF的阴性表达 (IHC×400)

    Figure  2   Negative MIF expression in gastric mucosae tissues (IHC×400)

    图  3   MIF高表达和低表达与贲门癌患者5年生存率的关系

    Figure  3   Relationship between high and low expression of MIF and 5-year survival rates of cardiac carcinoma patients

    表  1   MIF表达与贲门癌患者临床病理特征的关系

    Table  1   Relationship between MIF expression and clinicopathological features of cardiac carcinoma patients

    下载: 导出CSV

    表  2   贲门癌患者多因素Cox模型分析结果

    Table  2   Multivariate analysis of cardiac carcinoma patients by Cox regression

    下载: 导出CSV
  • [1]

    Morris KT, Nofchissey RA, Pinchuk IV, et al. Chronic macrophage migration inhibitory factor exposure induces mesenchymal epithelial transition and promotes gastric and colon cancers[J]. PLoS One, 2014, 9(6): e98656. doi: 10.1371/journal.pone.0098656

    [1] Morris KT, Nofchissey RA, Pinchuk IV, et al. Chronic macrophage migration inhibitory factor exposure induces mesenchymal epithelial transition and promotes gastric and colon cancers[J]. PLoS One, 2014, 9(6): e98656.
    [2] Babu SN, Chetal G, Kumar S. Macrophage migration inhibitory factor: a potential marker for cancer diagnosis and therapy[J]. Asian Pac J Cancer Prev, 2012, 13(5): 1737-44.
    [2]

    Babu SN, Chetal G, Kumar S. Macrophage migration inhibitory factor: a potential marker for cancer diagnosis and therapy[J].Asian Pac J Cancer Prev, 2012, 13(5): 1737-44. doi: 10.7314/APJCP.2012.13.5.1737

    [3] Zheng YX, Yang M, Rong TT, et al. CD74 and marcophage migration inhibitory factor as therapeutic targets in gastric cancer[J]. World J Gastroenterol, 2012, 18(18): 2253-61.
    [3]

    Zheng YX, Yang M, Rong TT, et al. CD74 and marcophage migration inhibitory factor as therapeutic targets in gastric cancer[J]. World J Gastroenterol, 2012, 18(18): 2253-61. doi: 10.3748/wjg.v18.i18.2253

    [4]

    Simpson KD, Templeton DJ, Cross JV. Macrophage Migration Inhibitory Factor promotes tumor growth and metastasis by inducing Myeloid Derived Suppressor Cells in the tumor microenvironment[J]. J Immunol, 2012, 189(12): 5533-40. doi: 10.4049/jimmunol.1201161

    [4] Simpson KD, Templeton DJ, Cross JV. Macrophage Migration Inhibitory Factor promotes tumor growth and metastasis by inducing Myeloid Derived Suppressor Cells in the tumor microenvironment[J]. J Immunol, 2012, 189(12): 5533-40.
    [5]

    Gámez-Pozo A, Sánchez-Navarro I, Calvo E, et al. PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free Proteomics[J]. PLoS One, 2012, 7(3): e33752. doi: 10.1371/journal.pone.0033752

    [5] Gámez-Pozo A, Sánchez-Navarro I, Calvo E, et al. PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free Proteomics[J]. PLoS One, 2012, 7(3): e33752.
    [6]

    Zhang L,Ye SB, Ma G, et al. The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma[J]. J Transl Med, 2013, 11: 60. doi: 10.1186/1479-5876-11-60

    [6] Zhang L,Ye SB, Ma G, et al. The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma[J]. J Transl Med, 2013, 11: 60.
    [7] Li H, Zang J, Wang P, et al. Gastric cancer susceptibility in gastric cancer relatives: attributable risks of Macrophage migration inhibitory factor promoter polymorphism and Helicobacter pylori[J]. Cytokine, 2012, 60(2): 346-51.
    [7]

    Li H, Zang J, Wang P, et al. Gastric cancer susceptibility in gastric cancer relatives: attributable risks of Macrophage migration inhibitory factor promoter polymorphism and Helicobacter pylori[J]. Cytokine, 2012, 60(2): 346-51. doi: 10.1016/j.cyto.2012.07.015

    [8]

    Li J, Mo HY, Xiong G, et al. Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients[J]. J Biol Chem, 2012, 287(42): 35484-95. doi: 10.1074/jbc.M112.367532

    [8] Li J, Mo HY, Xiong G, et al. Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17- producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients[J]. J Biol Chem, 20 12, 287(42): 35484-95.
    [9] 蔡滕, 吴苏稼, 樊根涛. 等. 巨噬细胞移动抑制因子在骨肉瘤中 的表达及其与预后的关系[J]. 临床肿瘤学杂志, 2013, 18(2): 12 3-5. [Cai T, Wu SJ, Fan GT, et al. Expression of macrophage migration inhibitory factor in osteosarcoma and its correlation with prognosis[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2013, 18 (2): 123-5.]
    [9] 蔡滕, 吴苏稼, 樊根涛. 等. 巨噬细胞移动抑制因子在骨肉瘤中的表达及其与预后的关系[J]. 临床肿瘤学杂志, 2013, 18(2): 123-5. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201302008.htm

    Cai T, Wu SJ, Fan GT, et al. Expression of macrophage migration inhibitory factor in osteosarcoma and its correlation with prognosis[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2013, 18(2): 123-5. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201302008.htm

    [10] 夏娟, 李冬, 郑伟萍, 等. 炎症与肿瘤的关系研究进展[J]. 国际检验医学杂志, 2013, 34(1): 63-4. http://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ201301033.htm

    Xia J, Li D, Zheng WP, et al. Research progress on relationship between inflammation and tumor[J]. Guo Ji Jian Yan Yi Xue Za Zhi, 2013, 34(1): 63-4. http://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ201301033.htm

    [10] 夏娟, 李冬, 郑伟萍, 等. 炎症与肿瘤的关系研究进展[J]. 国际 检验医学杂志, 2013, 34(1): 63-4. [Xia J, Li D, Zheng WP, et al. Research progress on relationship between inflammation and tumor[J]. Guo Ji Jian Yan Yi Xue Za Zhi, 2013, 34(1): 63-4.]
    [11] 赵德利, 陈万青, 于婷婷, 等. 贲门癌发病危险因素的病例对照 研究[J] 中华肿瘤杂志, 2011, 33(10): 775-8. [Zhao DL, Chen WQ, Ding TT, et al. A population-based matched case-control study on the risk factors of gastric cardia cancer[J]. Zhonghua Zhong Liu Za Zhi, 2011, 33(10): 775-8.]
    [11] 赵德利, 陈万青, 于婷婷, 等. 贲门癌发病危险因素的病例对照研究[J]. 中华肿瘤杂志, 2011, 33(10): 775-8. http://www.cqvip.com/qk/93685x/201110/39798275.html

    Zhao DL, Chen WQ, Ding TT, et al. A population-based matched case-control study on the risk factors of gastric cardia cancer[J]. Zhonghua Zhong Liu Za Zhi, 2011, 33(10): 775-8. http://www.cqvip.com/qk/93685x/201110/39798275.html

    [12] 欧玉荣, 康敏, 周蕾, 等. 胃癌中幽门螺旋杆菌L型感染与MIF、 MMP9、VEGF表达的关系[J]. 南方医科大学学报, 2014, 34(2): 18 0-7. [Ou YR, Kang M, Zhou L, et al. Infection with L-form of Helicobacter pylori and expressions of MIF, MMP9 and VEGF in gastric carcinoma[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2014, 34 (2): 180-7.]
    [12] 欧玉荣, 康敏, 周蕾, 等. 胃癌中幽门螺旋杆菌L型感染与MIF、MMP9、VEGF表达的关系[J]. 南方医科大学学报, 2014, 34(2): 180-7. http://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201402008.htm

    Ou YR, Kang M, Zhou L, et al. Infection with L-form of Helicobacter pylori and expressions of MIF, MMP9 and VEGF in gastric carcinoma[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2014, 34(2): 180-7. http://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201402008.htm

    [13] Arenberg D, Luckhardt TR, Carskadon S, et al. Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair[J]. Am J Respir Crit Care Med, 2010, 18 2(8): 1030-7.
    [13]

    Arenberg D, Luckhardt TR, Carskadon S, et al. Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair[J]. Am J Respir Crit Care Med, 2010, 182(8): 1030-7. doi: 10.1164/rccm.201001-0120OC

    [14] 徐慧鲜, 吴礼浩, 马伟钦, 等. 靶向MIF的siRNA对大肠癌细胞增殖的影响[J]. 中华全科医学, 2013, 11(3): 334-5. http://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201303003.htm

    Xu HX, Wu LH, Ma WQ, et al. The Effect of the Small Interfering Rnas for Macrophage Migration Inhibitory Factor on the Proliferation of Colorectal Cancer Cell Line[J]. Zhonghua Quan Ke Yi Xue, 2013, 11(3): 334-5. http://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201303003.htm

    [14] 徐慧鲜, 吴礼浩, 马伟钦, 等. 靶向MIF的siRNA对大肠癌细胞 增殖的影响[J]. 中华全科医学, 2013, 11(3): 334-5. [Xu HX, Wu LH, Ma WQ, et al. The Effect of the Small Interfering Rnas for Macrophage Migration Inhibitory Factor on the Proliferation of Colorectal Cancer Cell Line[J]. Zhonghua Quan Ke Yi Xue, 2013, 11 (3): 334-5.]
    [15] 张洪典, 唐鹏, 段晓峰, 等. 贲门癌淋巴结外软组织转移的临床病理特征及预后分析[J]. 中华外科杂志, 2013, 51(10): 882-6.

    Zhang HD, Tang P, Duan XF, et al. Analysis of the clinicopathologic characters and prognostic impact of extranodal metastasis in gastric cardia patients[J]. Zhonghua Wai Ke Za Zhi, 2013, 51(10): 882-6.

    [15] 张洪典, 唐鹏, 段晓峰, 等. 贲门癌淋巴结外软组织转移的 临床病理特征及预后分析[J]. 中华外科杂志, 2013, 51(10): 88 2-6. [Zhang HD, Tang P, Duan XF, et al. Analysis of the clinicopathologic characters and prognostic impact of extranodal metastasis in gastric cardia patients[J]. Zhonghua Wai Ke Za Zhi, 20 13, 51(10): 882-6.]
    [16] 丁学伟, 王晓娜, 薛强, 等. 贲门癌的临床病理特征分析[J]. 中 华肿瘤防治杂志, 2010, 17(10): 770-2. [Ding XW, Wang XN, Xue Q, et al. Clinicomathological characteristics of gastric cardia cancer[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2010, 17(10): 77 0-2.]
    [16] 丁学伟, 王晓娜, 薛强, 等. 贲门癌的临床病理特征分析[J]. 中华肿瘤防治杂志, 2010, 17(10): 770-2. http://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201010018.htm

    Ding XW, Wang XN, Xue Q, et al. Clinicomathological characteristics of gastric cardia cancer[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2010, 17(10): 770-2. http://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201010018.htm

    [17] Hosokawa Y, Kinoshita T, Konishi M, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan[J]. Ann Surg Oncol, 20 12, 19(2): 677-83.
    [17]

    Hosokawa Y, Kinoshita T, Konishi M, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan[J]. Ann Surg Oncol, 2012, 19(2): 677-83. doi: 10.1245/s10434-011-1983-x

图(3)  /  表(2)
计量
  • 文章访问数:  1239
  • HTML全文浏览量:  339
  • PDF下载量:  221
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-11-24
  • 修回日期:  2016-05-06
  • 网络出版日期:  2024-02-04
  • 刊出日期:  2016-08-31

目录

/

返回文章
返回
x 关闭 永久关闭